Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci

Clinical Infectious Diseases

Volumn 29, Issue 6, 1999, Pages 1566-1568

  Franchi, Diane ^a,b,c   Climo, Michael W ^b   Wong, Alice H M ^a,b   Edmond, Michael B ^a,b   Wenzel, Richard P ^a,b  

^a Division of Quality Health Care   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; ENTEROCOCCUS; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; POPULATION RESEARCH; PRIORITY JOURNAL; SCREENING TEST; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCOCCUS; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; TIME FACTORS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 0033401331     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313530     Document Type: Article

References (13)

1. 1. Kaplan AH, Gilligan PH, Facklam RR. Recovery of resistant enterococcus during vancomycin prophylaxis. J Clin Microbiol 1988;26:1216-8.
2. 2. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195-8.
3. 3. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997;179:2557-66.
4. 4. Centers for Disease Control and Prevention. Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996. MMWR Morb Mortal Wkly Rep 1997;46:624-6.
5. 5. Centers for Disease Control and Prevention. Update: Staphylocaccus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:813-5.
6. 6. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.
7. 7. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340:517-23.
8. 8. Rotun SS, McMath V, Schoonmaker DJ, et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999;5:147-9.
9. 9. Wenzel RP, Edmond MB. Vancomycin-resistant Staphylococcus aureus: infection control considerations. Clin Infect Dis 1998;27:245-9.
10. 10. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital [letter]. Lancet 1998;351:1212.
11. 11. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 4th ed. Vol. 17, no. 2. NCCLS document M7-A4. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997.
12. 12. Tenover FC, Lancaster ML, Hill BC, Steward CD, Stocker SA, Hancock GA. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36:1020-7.
13. 13. Climo MW, Patron RL, Archer GL. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother 1999;43:1747-53.